Search Within

Department of Medicine

Formats
  1. Journal Article (19618)
  2. Meeting Abstract (16046)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22348)
  2. Hematologic Malignancies, Division of (13287)
  3. Center for Hematologic Malignancies (11069)
  4. GSK Faculty (10653)
  5. Survivorship Research (9346)
  6. Division of Subspecialty Medicine (7554)

More Groups

People
  1. Robert Motzer (1249)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1118)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2291)
  6. Nature Publishing Group (2121)

More Publishers

Results (39669)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma
    Meeting Abstract

    Smith, J. W.; Ko, Y. J.; Dutcher, J.; Hudes, G.; Escudier, B.; Motzer, R.; Negrier, S.; Duclos, B.; Galand, L.; Strauss, L.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders
    Meeting Abstract

    Sklarin, N. T.; Timoney, J.; Kampel, L.; Hydzik, C.; Savage, J.; Capobianco, M.; Miransky, J.; Haspel, J.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • TP53 and CHEK2*1100delC gene mutation in North American families suggestive Li-Fraumeni syndrome: Memorial Sloan-Kettering experience
    Meeting Abstract

    Siddiqui, R.; Diaz, L. R.; Nafa, K.; Kauff, N.; Facio, F.; Huang, H.; Onel, K.; Robson, M.; Ellis, N.; Offit, K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • The role of Notch pathway in glial tumorigenesis
    Meeting Abstract

    Shih, A.; Holland, E.
    Neuro-Oncology (2004)

    Fulltext@MSK | Save
  • A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)
    Meeting Abstract

    Shah, M. A.; Kortmansky, J.; Gonen, M.; Tse, A.; Lefkowitz, R.; Kelsen, D.; Colevas, D.; Winkelman, J.; Yi, S.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
    Meeting Abstract

    Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Dressler, L.; Muss, H.; Norton, L.; Winer, E.; Hudis, C.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Response assessment parameters in esophageal cancer - Conventional and novel techniques
    Meeting Abstract

    Schwartz, L. H.; Colville, J. A. C.; Wang, L.; Hricak, H.; Ilson, D.; Schwartz, G. K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
    Meeting Abstract

    Saltz, L. B.; Niedzwiecki, D.; Hollis, D.; Goldberg, R. M.; Hantel, A.; Thomas, J. P.; Fields, A. L. A.; Carver, G.; Mayer, R. J.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Targeting tumors with genetically enhanced T lymphocytes
    Meeting Abstract

    Sadelain, M.
    Blood Cells, Molecules, and Diseases (2004)

    Fulltext@MSK | Save
  • Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer
    Meeting Abstract

    Sabbatini, P.; Aghajanian, C.; Dupont, J.; Derosa, F.; Anderson, S.; McGuire, W.; Rodabaugh, K.; Ferrone, S.; Lele, S.; Odunsi, K.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save